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Pulmonary infection is still a major health concern in Indonesia, and fungal infection is emerging. This 
may be related to widely used broad spectrum antibiotics, steroids, oral contraceptive, cytostatic, and 
chronic diseases.The aim of this study was to describe Candida spp sensitivity pattern to various 
antifungal agents from pulmonary tuberculosis suspected patients. In this study, we used 176 sputum 
samples from tuberculosis suspected patients. The samples were cultured 3 times in Sabouraud 
dextrose agar. Yeast was identified by API 20 C AUX, while antifungal susceptibility test used ATB 
FUNGUS 3. There were 85 samples infected by yeast.  As many as 74 isolates were identified as C. 
albicans (87.1%), 9 isolates were C. tropicalis (10.6%) and 2 were C. dubliniensis (2.4%). The 
susceptibility test showed six isolates of C. albicans and one isolate of C. tropicalis were intermediate 
against itraconazole. Only three isolates of C. albicans were resistant against itrazonazole, 
fluconazole, and voriconazole. Fortunately, they were still sensitive to amphotericine B and 
flucytosine. Almost half of tuberculosis suspected patients were infected by Candida spp. Most of 
them were still sensitive to various antifungal agents, although few C. albicans isolates were resistant 
against fluconazole, itraconazole, voriconazole.  
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INTRODUCTION 
 
Fungal pulmonary infection has been emerging recently 
due to widely used broad spectrum antibiotics and 
steroids (Nucci and Marr, 2005). It can be acquired 
primarily or secondarily in tuberculosis, immunodeficiency 
patients, other chronic diseases such as diabetes mellitus 
or malignancy, and may worsen the primary disease 
(Baradkar et al., 2009; Ozcelik et al., 2004; Kovacicova et 
al., 2000; Satana et al., 2010; Basu et al., 2010) Many 
physicians missed fungal pulmonary infection because it 
doesn’t show specific clinical manifestations and usually 
hindered by other diseases (Pfaller and Diekema, 2007). 
Therapeutic approach to fungal pulmonary infection has  
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become attention due to several cases of resistance 
against antifungal agents (Dimopoulos et al., 2009; Lyon 
et al., 2010). 
  
 
METHODS 
 
The samples were taken consecutively from April 2009 to 
August 2010 from two hospitals and two primary health 
care facilities in Jakarta  The participants were pulmonary 
tuberculosis suspected patients. The inclusion criteria 
were: age ≥15 year old suspected pulmonary 
tuberculosis that fulfilled at least two of these symptoms: 
cough for ≥2 weeks, hemoptysis, dyspnoe, chest pain, 
night sweat, fever, weight loss. Sputum was collected 
within three consecutive days in the morning. Samples 
were excluded if  participants denied to sign the informed 
consent, cannot collect  three  sputum  samples  conse-  
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Table 1.  Patients’ characteristic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n = 176 
 
 
Table 2. Sensitivity pattern of Candida spp to flucytosine, amphotericin, fluconazole, itraconazole and voriconazole 
 
Species 
 (number of 
isolates) 
Antifungal agents Sensitive(%) Intermediate(%) Resistant (%) 
Candida albicans flucytosine 74(100)   
(74) amphotericin B 74(100)   
 fluconazole 71(95.9)  3(4.1) 
 itraconazole 65(87.8) 6(8.1) 3(4.1) 
 voriconazole 71(95.9)  3(4.1) 
     
C. tropicalis flucytosine 9(100)   
(9) amphotericin B 9(100)   
 fluconazole 9(100)   
 itraconazole 8(88.9) 1(11.1)  
 voriconazole 9(100)   
     
C. dublienensis flucytosine 2(100)   
 amphotericin B 2(100)   
 fluconazole 2(100)   
 itraconazole 2(100)   
 voriconazole 2(100)   
 
 
 
cutively, and the culture result revealed mold. Sputum 
was collected from 176 suspected pulmonary 
tuberculosis patients after informed consent.   
The samples were examined three times by cultured 
in Sabouroud dextrose agar. If the culture had given 
positive result, it was then identified for yeast by API 20 C 
AUX (bioMerieux S.A Marcy-1”Etoile France, 2007) and 
sensitivity test against antifungals by ATB FUNGUS 3 
(bioMerieux S.A Marcy-1”Etoile France, 2007). The 
examination fulfilled the standard of CLSI, document 
M27-A3 (Clinical and Laboratory Standars 
Institute(CLSI). Reference method for broth dilution 
antifungal susceptibility testing of yeasts, 3rd ed 
Approved standard CLSI M27-A3 Clinical and Laboratory 
Standards Institute, Wayne, PA 2008). 
 
 
RESULTS AND DISCUSSIONS  
 
There were 108 men, age ranged 25-78 years old (mean 
53 years old), and 68 wome, age 19-76 years old (mean 
48 years old) (table 1).   
From 176 samples, 97 (55.1%) were fungi (12 molds 
and and 85 yeasts) and 79 were negative. As listed in 
table 2, from 85 (48.3%) yeasts isolates, most of them 
were C. albicans, followed by C. tropicalis, and C. dubli-  
 Sample  
   Patients Number % 
Age group (years)   
15-19 2 1.1 
20-29 29 6.5 
30-39 26 14.8 
40-49 40 22.7 
50-59 44 25.0 
60-69 16 9.1 
> 70 19 10.8 
Sex   
Male 108 61.5 
Female 68 38.6 
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niensis. Table 2 also shows sensitivity test of Candida 
spp against antifungal regimens.  
Six isolates of C. albicans and one isolate of C. 
tropicalis gave intermediate results against itraconazole. 
Only three isolates, all were C. albicans, were resistant 
against fluconazole, itraconazole, and voriconazole.  
About 55.1% of the samples were infected by fungi. 
Study by Suryatenggara et al in 1995 found less, that 
was about 45% of bronchial wash samples infected by 
fungi (Suryatenggara et al., 1995). Baradkar et al6 
reported 26% tuberculous patients were infected by 
yeast, much less than 48.3% found in our study. 
Frequent and irrationale antibiotic use, especially broad 
spectrum, was considered the cause of this phenomen.  
From all the yeast isolated, most of them were C. 
albicans, C. tropicalis, and C. dubliniensis. Study by 
Baradkar et al., 2009; Jha et al., 2006; Basu et al., 2003, 
and Makaddas et al., 2005 also reported that C. albicans 
was the most frequent yeast isolated. 
All of Candida spp in this study were still sensitive to 
flucytosine and amphotericine B. This is in accordance 
with study by Fleck et al, which may be caused by 
seldom use of the drugs (Fleck et al., 2005). On the other 
hand, some of C. tropicalis and C. albicans gave 
intermediate and resistant results to itraconazole and 
fluconazole, maybe because the drugs are more 
frequently used in community. 
 
 
CONCLUSION 
 
In this study, almost half of tuberculosis suspected 
patients were infected by Candida spp. Most of them 
were still sensitive to various antifungal agents, although 
few C. albicans isolates were resistant against 
fluconazole, itraconazole, voriconazole. This may lead us 
to consideration of trend toward increasing resistance 
rate of Candida spp against antifungal agents. 
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